• Zura Bio highlighted tibulizumab, a bispecific antibody designed to inhibit IL-17 and BAFF in complex autoimmune disease.
• Two Phase 2 trials ongoing: hidradenitis suppurativa readout expected in Q4 2026; systemic sclerosis readout expected in 1H 2027.
• Cash and cash equivalents of ~$225.6 million as of March 31, 2026; February 2026 offering expected to fund operations through at least end-2028.
• ~124 million shares outstanding as of March 31, 2026 on an as-converted basis, including shares issuable on pre-funded warrant conversion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.